Voiant Delivers Primary Endpoints in Two New Drug Approvals for Colorectal Cancer and Glioma Following Successful FDA Inspections
WALTHAM, Mass. / PRNewswire-PRWeb
Voiant, a leader in AI-driven clinical trial imaging, supported the FDA approvals of two cancer treatments for colorectal cancer and glioma by delivering key imaging endpoints for pivotal trials. Following successful FDA inspections of its processes and Voiant Hub platform, the approvals reinforce Voiant’s role as a trusted partner in drug development, contributing to over 70 approvals across multiple therapeutic areas and agencies.
Voiant, the industry’s leading AI-driven clinical trial imaging solution provider, is proud to announce that the primary endpoints it delivered for two independent pivotal trials have resulted in the approval of two groundbreaking drugs for the treatment of colorectal cancer (CRC) and glioma. The approvals were achieved following the successful U.S. Food and Drug Administration (FDA) inspections of Voiant’s procedures, organizational structure, and Voiant’s imaging platform Voiant Hub. This significant milestone underscores Voiant’s mission to accelerate the development of innovative treatments for patients in need. The primary endpoints provided by Voiant were Progression Free Survival (PFS) assessed by Response Evaluation Criteria in Solid tumor (RECIST v1.1) for CRC and Response Assessment in Neuro-Oncology (RANO) for glioma.
CRC is the third most frequently diagnosed cancer and the second leading cause of cancer-related deaths worldwide. Gliomas, a group of aggressive brain tumors, are responsible for most deaths among patients with primary brain tumors due to their high malignancy, recurrence risk, and limited treatment options. The approval of these new treatments offers hope to millions of patients affected by these devastating diseases.
This achievement reinforces Voiant’s reputation as a trusted partner for top biotech and pharmaceutical companies worldwide. With an unwavering commitment to speed and precision, Voiant has now contributed to more than 70 drug approvals across Oncology, Respiratory, and Ophthalmology, solidifying its leadership in delivering imaging endpoints in support of healthcare advancement.
Jim Primerano, CEO of Voiant, shared his thoughts on the accomplishment:
“We are humbled and honored to have supported the successful trials that led to these new drug approvals. At the heart of what we do is a commitment to helping patients in need, and these approvals exemplify the very core of our mission.”
Voiant remains dedicated to collaborating with industry leaders to bring transformative therapies to the market, ensuring patients have access to the treatments they need as quickly as possible. These recent successes underscore the company’s focus on excellence in clinical development and regulatory compliance.
For more information about Voiant and its services, please visit www.voiantclinical.com .
About Voiant
Voiant is the industry-leading AI-based clinical trial imaging solution provider with unparalleled scientific and clinical domain expertise, providing biopharmaceutical companies with high-speed delivery of quality clinical endpoint data. Additional information is available at www.voiantclinical.com.
SOURCE Voiant
Media Contact
Stephane Deleger, Voiant
+1.888.963.3742
info@voiantclinical.com
www.voiantclinical.com